Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion

Cardiovascular protein therapeutics such as neuregulin (NRG1) and acidic-fibroblast growth factor (FGF1) requires new formulation strategies that allow for sustained bioavailability of the drug in the infarcted myocardium. However, there is no FDA-approved injectable protein delivery platform due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Garbayo, Elisa, Gavira, Juan José, de Yebenes, Manuel Garcia, Pelacho, Beatriz, Abizanda, Gloria, Lana, Hugo, Blanco-Prieto, María José, Prosper, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868965/
https://www.ncbi.nlm.nih.gov/pubmed/27184924
http://dx.doi.org/10.1038/srep25932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868965/
https://www.ncbi.nlm.nih.gov/pubmed/27184924
http://dx.doi.org/10.1038/srep25932

Ejemplares similares